Nassim Usman, Catalyst Biosciences CEO

Fac­ing set­backs for months and an ac­tivist at­tack, Cat­a­lyst Bio­sciences pre­pares to call it quits

Af­ter down­siz­ing for sev­er­al months, Cat­a­lyst Bio­sciences is get­ting ready to tap out.

The San Fran­cis­co biotech an­nounced Wednes­day that it would be liq­ui­dat­ing and dis­trib­ut­ing cash back to share­hold­ers, with to­tal pro­ceeds ex­pect­ed to reach $65 mil­lion. Cat­a­lyst in­tends to re­turn the mon­ey “as soon as prac­ti­ca­ble,” the com­pa­ny said, as it has ceased all R&D ac­tiv­i­ties, CEO Nas­sim Us­man said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.